US Stock MarketDetailed Quotes

BBIO BridgeBio Pharma

Watchlist
  • 36.420
  • 0.0000.00%
Close Apr 29 16:00 ET
  • 38.070
  • +1.650+4.53%
Pre 09:27 ET
6.92BMarket Cap-10.23P/E (TTM)

About BridgeBio Pharma Company

BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Francis Patrick McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.

Company Profile

SymbolBBIO
Company NameBridgeBio Pharma
Listing DateJun 27, 2019
Issue Price17.00
Founded2015
CEODr. Neil Kumar, PhD
MarketNASDAQ
Employees730
Fiscal Year Ends12-31
Address3160 Porter Drive,Suite 250
CityPalo Alto
ProvinceCalifornia
CountryUnited States of America
Zip Code94304
Phone1-650-391-9740
Websitehttp://www.bridgebio.com

Company Executives

  • Name
  • Position
  • Salary
  • Dr. Neil Kumar, PhD
  • Director and Chief Executive Officer of the Company and Eidos Therapeutics, Inc.
  • 12.16M
  • Maricel M. Apuli
  • Chief Accounting Officer
  • --
  • Dr. Thomas Trimarchi, PhD
  • Principal Financial Officer and President
  • --
  • Dr. Richard H. Scheller, PhD
  • Chairman of Research & Development
  • 2.01M
  • Dr. Charles J. Homcy,M.D.
  • Lead Independent Director and Chairman of Pharmaceuticals
  • 1.11M
  • Dr. Frank P. McCormick, D.Sc.
  • Director
  • 1.74M
  • Jennifer E. Cook
  • Independent Director
  • 600.00K
  • Andrea John Ellis
  • Independent Director
  • 600.00K
  • Ronald J. Daniels
  • Independent Director
  • 600.00K
  • James C. Momtazee
  • Independent Director
  • 600.00K
  • Fred Hassan
  • Independent Director
  • 600.00K
  • Douglas A. Dachille
  • Independent Director
  • 600.00K
  • Ali J. Satvat
  • Independent Director
  • 600.00K
  • Dr. Randal W. Scott,PhD
  • Independent Director
  • 600.00K
  • Dr. Hannah A. Valantine, M.D.
  • Independent Director
  • 600.00K
  • Dr. Eric Aguiar, M.D.
  • Independent Director
  • 600.00K
  • Dr. Andrew W. Lo, PhD
  • Independent Director
  • 600.00K

Market Insights

Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries

Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.

No. Symbol Price
Meta Platforms
META
554.440
Coinbase
COIN
206.130
MARA Holdings
MARA
14.220
4
Petroleo Brasileiro SA Petrobras
PBR
11.520
5
Alphabet-A
GOOGL
160.160
Log In for the Full List
Unlock Now

Investment Course

Top 5 Industries for Stock Trading under Trump's Second Term
Stocks & Industries to Watch Under Trump's Second Presidency
With mooomoo, find out which stocks and industries may benefit from Trump's second presidency, based on his first administration's track record.

Discussing

Trump 2.0 Era: How will global markets evolve?
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context, Show More
MicroStrategy Q4 2024 earnings conference call

Reassessing Chinese Assets

Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.